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Abstract Crystal structures of DX9065a and a related bis- 
amidino-aryl inhibitor specific for the blood-clotting factor Xa 
have been solved in complex with bovine ~-trypsin to a resolution 
of 1.9 A. Each inhibitor exhibits an extended conformation along 
the active site, in contrast to the compact folded structures ob- 
served for thrombin specific inhibiturs. Few direct contacts (pre- 
dominantly in the S1 pocke0 are made between trypsin and the 
inhibitors. Transfer of the inhibitors to the active site of factor 
Xa suggests a three-site interaction: salt bridge formation at the 
base of the primary specificity pocket, extensive hydrophobie 
surface burial and a weak electrostatic interaction between the 
distal basic component of the inhibitor and an electronegative 
cavity of factor Xa formed by three backbone carbonyl oxygens. 
Additivity of these three interactions is the basis for the observed 
strong inhibition of factor Xa and provides a framework for the 
design of novel factor Xa inhibitors. A propionic acid group of the 
inhibitor would clash with the thrombin specific '60-insertion 
loop', thus conferring selectivity against thrombin. 
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I. Introduction 
The prevention of blood coagulation is of primary impor- 
tance in a variety of pathological situations. Conventional nti- 
coagulant treatment includes the administration ofheparin and 
coumarins (warfarin). A number of limitations are associated 
with these, however [1]. Heparin acts indirectly as an anticoag- 
ulant by promoting the inhibition of a-thrombin by antithrom- 
bin and is, therefore, unable to inhibit clot bound thrombin; 
warfarin disrupts the vitamin K-dependent synthesis of many 
of the coagulation enzymes and must, therefore, be monitored 
very carefully. The development of directly acting low molecu- 
lar weight inhibitors of the coagulation factors has, therefore, 
become attractive. 
Much emphasis has been put upon inhibitors of thrombin, 
the ultimate protease of the coagulation cascade. The X-ray 
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N~-(2-napthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine; 
PDB, Protein Data Bank. 
crystal structure of human a-thrombin [2,3] has been of value 
in identifying structural requirements for its inhibition [4]. The 
central role played by thrombin in haemostasis in both coagu- 
latory and anticoagulatory processes (see [5]) suggests that its 
inhibition may not be desirable in all clinical settings, however. 
One attractive line of attack is to disrupt he thrombin cata- 
lyzed amplification reactions. This could be achieved through 
inhibition of factor Xa, the enzyme directly responsible for 
thrombin activation. Inhibition of factor Xa interrupts both the 
extrinsic and intrinsic pathways of thrombin production, whilst 
allowing the thrombin catalyzed activation of protein C. The 
efficacy of factor Xa inhibition is demonstrated by the antico- 
agulant properties of the factor Xa specific inhibitors antistasin 
[6] and tick anticoagulant peptide [7] derived from haemato- 
phagous parasites. 
Synthetic factor Xa specific inhibitors have been described 
in the literature [8-10]. The most potent inhibitors consist of 
two basic moieties eparated by a spacer of appropriate l ngth 
(Fig. 1). Daiichi compound DX9065a ((+)-2-[4-[((3S)-l-acet- 
imidoyl-3-pyrrodinyl)oxy]phenyl]-3-(7-amidino-2-napthyl)pro- 
pionic acid) exhibits a K~ of 41 nM for factor Xa, no activity 
against hrombin and displays ome oral activity [11]. The in- 
hibitor has been modelled to the active sites of factor Xa, 
thrombin and human trypsin [10,12-13]. In each case, the mod- 
els suggest an extended conformation of the inhibitor. The 
inherent flexibility of the molecule precludes an exhaustive 
search of possible conformational space, however, and, there- 
fore, the interaction mechanism is still a matter of debate. 
Experimental crystallographic data are necessary to establish 
the binding mode unequivocally. 
The recent crystallographic structure determination offactor 
Xa [14] provides an opportunity to apply a structure-based 
approach to the search for specific inhibitors. However, the 
active site of factor Xa is blocked in the crystal form examined 
and no crystals of inhibited factor Xa have been reported as yet. 
The success in determining the mode of action of thrombin 
specific inhibitors by introducing them into crystals of trypsin 
[15-17], subsequently verified by their crystal structures in com- 
plex with thrombin [18,19] prompted us to investigate the bind- 
ing of factor Xa inhibitors to the active site of trypsin. In this 
communication, we present hree structures of compounds of 
the Daiichi class in complex with bovine fl-trypsin, indicating 
structural requirements for the inhibition of factor Xa for the 
first time. 
2. Experimental 
Bovine fl-trypsin was separated from commercial trypsin (Merck, 
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Darmstadt, Germany) by ion-exchange chromatography. Crystals for 
soaking experiments were grown from small seeds of the 'open' form 
in 1.7-1.8 M ammonium sulphate, pH 6.0, as described [16]. Crystals 
were soaked for 2 days in approximately 2 mM inhibitor solution, 2.5 
M ammonium sulphate, pH 8.0. Due to problems of insolubility of 
some of the inhibitors in this high salt buffer, cocrystallization experi- 
ments were also carried out. Trypsin with approximately 1 mM inhib- 
itor was crystallized by vapour diffusion against 20-30% polyethylene 
glycol 8000, 0.1-0.3 M ammonium sulphate, pH 7-8. 
Data were collected on a Centronics area detector (Siemens) and 
processed using XDS [20]. Starting coordinates [16,21,22] were taken 
from the Protein Data Bank [23] according to the space group (Table 
1). Conventional crystallographic refinement (rigid body, positional 
and temperature factor) was carried out using XPLOR [24,25]. Molec- 
ular models of the inhibitors were constructed using SYBYL (Tripos 
Associate) and model building performed using O [26]. Coordinates of 
the inhibitors were transferred to those of factor Xa [14] (PDB code 
lhcg.pdb) and human c~-thrombin [27] (PDB code lfph.pdb) through 
superposition of conserved residues around the active sites of trypsin, 
factor Xa and thrombin using the programme O [26]. Data collection 
and refinement s atistics are given in Table 1. 
3. Results 
BX5633 was successfully soaked into the 'open' trypsin crys- 
tal form. As attempts to soak DX9065a were unsuccessful, 
cocrystallization experiments were also performed. Two space 
groups were obtained: one orthorhombic (DX9065a), related 
to the crystal form observed for p-amidinophenylpyruvate- 
trypsin [21] and one trigonal (BX5633), isomorphous to free 
bovine trypsin [22] (Table 1). The conformation of trypsin 
DX9065a 
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Fig. 1. Chemical formulae and inhibition constants for potent factor Xa 
specific inhibitors. DX9065a: (+)-2-[4-[((3S)-l-acetimidoyl-3-pyrrod- 
inyl)oxy]phenyl]-3-(7-amidino-2-napthyl) propionic acid; BX5633: (+)- 
2-[4-[(-1 -acetimidoyl-4-piperidinyl) oxy]phenyl]-3 (7-amidino-2-nap- 
thyl) propionic acid; DABE: 1,2-di-(5-amidino-2-benzofuranyl) ethane; 
BABCH: 2,7-bis-(4-amidinobenzilidene)-cycloheptan-l-one. DX9065a 
and BX5633 were supplied as racemic mixtures at the chiral carbon 
atom marked with an asterisk. K~ values (for human enzyme unless 
otherwise stated) are taken from (a) Hara et al. (1994) [11], (d) Tidwell 
et al. (1980) [8] and (e) Stiirzebecher tal. (1989) [9]; IC5o values (italic) 
are given for (b) the + and - epimers and the racemic mixture of 
DX9065a, Nagahara et al. (1994) [28] and (c) for BX5633, Nagahara, 
T., Kanaya, N., Inamura, K. and Yokoyama, Y. (1992), European 
Patent Application No. 0 540 051 A1. 
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Fig. 2. 'Omit' electron densities for factor Xa specific inhibitors in 
complex with bovine fl-trypsin. (a) Electron density for BX5633 soaked 
into the 'open' trypsin form. Broken density at the attachment for the 
propionic acid reveals that both enantiomers are bound in the crystal, 
both of which can be modelled into the density. Thick connections 
denote the (+) epimer, medium lines the (-) epimer. (b) Cocrystal of 
DX9065a; note that the pyrrolidinyl ring makes a contact o a symme- 
try related molecule (thin lines). (c) Cocrystal of BX5633. The propionic 
acid moiety makes a salt bridge to a symmetry related lysyl side chain, 
presumably giving rise to preference for this stereoisomer. 
showed minor perturbations, largely associated with crystal 
packing. The only significant differences observed were in the 
side chain conformations of Gln-192 (which was partially disor- 
dered) and Gln-175. 
The inhibitors are in each case well-defined by electron den- 
sity (Fig. 2). Both compounds were supplied initially as racemic 
mixtures at the C15 atom (Fig. 1) and it is clear from the density 
for the soaked crystal that both enantiomers are present in the 
crystal (Fig. 2a). In the two cocrystal forms, only one stereoi- 
somer is observed bound to the enzyme (Fig. 2b,c). In both 
cocrystals, the inhibitor is stabilised by crystal contacts to the 
propionic acid group: via an ionic contact to a symmetry re- 
lated lysine side chain in the trigonal form (Fig. 2c) or via 
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Fig. 3. (a) Transfer of BX5633 (cocrystal) to the active site of factor Xa. 
The interaction is divided over three sites. The napthalene amidino 
group makes asalt bridge to Asp-189 of factor Xa, while the propionic 
acid moiety makes no contacts to the enzyme. The hydrophobic box 
formed by the side chains of Trp-215, Tyr-99 and Phe-174 is occupied 
by the benzyl spacer and the hydrophobic side of the piperidinyl ring. 
The distal basic group points towards an electronegative cavity on the 
surface of factor Xa, at the conjunction of carbonyl groups of Glu-97, 
Thr-98 and Ile- 175. (b) Transfer to the active site of human a-thrombin. 
The propionic acid 'selectivity filter' would clash with thrombin's rather 
rigid 60 loop; in addition, the 'electronegative cavity' is less open due 
to the insertion in thrombin of Glu-97A. 
~97 ARG 
99 LEU 
5:HIS 
ER 
hydrogen bonds made with backbone amide groups in the 
orthorhombic form (Fig. 2b). The free acetimidoyl group of 
DX9065a is further stabilised through contacts with a symme- 
try related carbonyl group (Fig. 2b). Comparison of the confor- 
mation of BX5633 in both the open and trigonal forms reveal 
minimal influence of crystal packing forces on the overall inter- 
Table 1 
Data collection and refinement s atistics 
action; on the other hand, the conformation of the pyrrolidine 
group of DX9065a is clearly crystal related. 
The inhibitors bind in extended conformation, filling the 
'unprimed' sites of trypsin. The bulky napthamidine moiety 
occupies the S1 site, filling it almost completely, with its amid- 
ino function forming a salt bridge with Asp-189. The rigid 
nature of the napthalene group results in a considerable dis- 
tance (> 3.5 A) between the enzyme surface and the aromatic 
benzyl 'spacer', which is oriented perpendicular to the 
napthalene group and parallel to the indole moiety of Trp-215. 
This conformation results in the propionic acid moiety pointing 
into solution away from the enzyme (Fig. 2). 
Outside the S1 pocket, the majority of contacts between the 
enzyme and inhibitors are made between the indole moiety of 
Trp-215 and the hydrophobic edge of the pyrrolidine (piperid- 
ine) ring, the plane of which is more or less perpendicular to
that of the benzyl spacer. For DX9065a, the pyrrolidine ring 
exhibits an envelope conformation, whilst the piperidine ring 
of BX5633 exhibits a chair conformation (Fig. 2). The ring 
nitrogens and acetimidoyl groups (Fig. 1) are all coplanar (Fig. 
2), suggesting electron delocalization within this group, and it 
is most probably protonated. The nitrogen atoms of the 
pyrrolidine (piperidine) ring and the acetimidoyl group ap- 
proach Gln-175 Oel ,  and are in the vicinity of the carbonyl 
oxygen of Asn-97. As mentioned above, the pyrrolidine group 
of DX9065a is involved in additional contacts to a symmetry 
related molecule. 
The inhibitors were transferred to the active site of factor Xa 
after superposition of its active site residues with those of tryp- 
sin (Fig. 3a). BX5633 fitted well to the surface of factor Xa 
without rearrangement. The pyrrolidine ring of DX9065a, on 
the other hand, would clash with the benzyl ring of factor Xa 
residue Phe-174. As discussed above, this conformation is influ- 
enced by crystal packing; DX9065a could follow a similar 
course to BX5633 through flipping of the envelope conforma- 
tion (cf. the endo-/exo-transition of furanose). In the following, 
the interaction with factor Xa and thrombin will be based on 
the cocrystal structure of trypsin with BX5633. 
The interaction appears dominated by the burial of the 
napthamidine group in the S1 pocket, which is slightly more 
hydrophobic due to the substitution of trypsin Ser-190 for Ala- 
190 in factor Xa. The benzyl 'spacer' of the inhibitor makes 
weak van der Waal's contacts to the longer phenolic side chain 
of Tyr-99, whose perpendicular rangement could marginally 
enhance binding through edge-on stacking (Fig. 3a). 
The environment of the acetimidoyl-piperidinyl moiety is 
Compound Crystallization Space- Cell constants Observed/ Rsy m Reflections 
conditions group unique > 3a 
reflections (comple- 
teness) 
Number of non-hydrogen atoms r .... Rf~o 
Protein Solvent Inhibitor Bonds Angles 
BX5633 t 1.8 M AS, pH 6.0 P2~2~2~ 63.3 69.3 63.8 49006/22069 2.9% 21173 (94.2%) 1628 163 
90. 90. 90. 
DX9065a 2 0.3 M AS, pH 8.0 P2~2~21 54.9 61.0 64.3 25539/16195 3.2% 14950 (86.3%) 1628 290 
30% PEG 8000 90.90. 90. 
BX56333 0.1 M AS, pH 7.0 P3t2 t 54.8 54.8 109.7 26673/14594 3.7% 13599 (88.4%) 1628 245 
20% PEG 8000 90. 90. 120. 
34 0.008 1.75 17.9 
33 0.009 1.99 16.9 
34 0.008 1.78 16.9 
~Soak crystal; isomorphous toNAPAP-trypsin [16] (PDB code lppc.pdb). 
2 Cocrystal; similar to p-amidinophenylpyruvate-trypsin (54.9 58.5 67.8 90. 90.90.) [21] (PDB code ltpp.pdb). 
3 Cocrystal; isomorphous to free trypsin [22] (PDB code 3ptn.pdb). 
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largely hydrophobic. The interaction between the edge of the 
piperidine ring and the side chain of Trp-215 is further en- 
hanced by the presence of the hydrophobic side chain of Phe- 
174. It is striking, however, that this basic group maps to an 
electronegative cavity on the surface of factor Xa formed by the 
juxtaposition of the carbonyl groups of Glu-97, Thr-98 and 
Ile-175. 
Transfer of BX5633 to the active site of thrombin reveals that 
the propionic acid group would clash with the relatively rigid 
'60 insertion loop' of thrombin (Fig. 3b). Furthermore, the 
electronegative cavity identified for factor Xa is less accessible 
due to the sequence insertion of residue Glu-97A in thrombin. 
Selectivity of these inhibitors against hrombin is, therefore, 
effected via steric hindrance. 
4. Discussion 
The compounds investigated here are amongst the most po- 
tent synthetic inhibitors of factor Xa known (Fig. 1). In com- 
mon with the simple symmetric molecules DABE and BABCH, 
these compounds exhibit a dibasic haracter. Structure-activity 
relationships for DX9065a have shown that the distal basic 
moiety plays a major role in the inhibition of factor Xa, whilst 
the propionic acid group is responsible for its lack of activity 
against hrombin [10]. Molecular modelling has attributed the 
basicity requirement variously to interaction with factor Xa 
Glu-97 [10], the carbonyl group of Glu-97 [12] or to a novel 
cationqr interaction with the aromatic rings of Trp-215, Tyr-99 
and Phe-174 [13]. Modelling studies have further proposed that 
selectivity against thrombin is due to electrostatic repulsion 
between the side chain of thrombin Glu-192 (Gln-192 in factor 
Xa) and the propionic moiety [10]. The distal basic moiety also 
has a (slight) detrimental effect on the inhibition of human 
trypsin [12], which possesses lysyl residues at both residues 97 
and 175. 
Comparing our structures with the published models, we 
note the following: 
(i) the propionic acid moiety faces towards Gly-219 in the 
models of Katakura et al. [10,12], instead of away from the 
enzyme. This results in an alternative approach of the distal 
basic group to the surface of factor Xa. In their most recent 
model [12], the dominant interaction of this group is to the 
carbonyl group of Glu-97, with fewer hydrophobic contacts; 
(ii) the overall inhibitor conformation proposed by Lin and 
Johnson [13] is much closer to that which we see. Due to a slight 
inclination of the napthalene group, however, the pyrrolidinyl 
group does not extend as far along the enzyme surface. In their 
model, therefore, the distal basic group does not reach the 
'electronegative cavity', but resides in the hydrophobic box 
formed by Tyr-99, Phe-174 and Trp-215, leading them to pro- 
pose an interaction between this group and the ~z electrons of 
these aromatic groups. 
Although these modelling studies give an idea about the 
general nature of the interaction, they possess an inherent un- 
certainty in the conformation of the inhibitor and cannot be 
totally objective. Despite the obvious differences between tryp- 
sin and factor Xa, if it is possible to transfer the coordinates 
from one active site to the other without major rearrangements, 
one can expect that the positioning of the inhibitor will be 
similar in each. A model derived in this fashion gains stature 
if improved interactions are made in factor Xa than in trypsin. 
This has been shown to be the case for thrombin specific inhib- 
itors [16-19], even though thrombin and trypsin exhibit even 
weaker similarity. 
Our results show that, in contrast o the compact folded 
conformations observed for thrombin specific inhibitors [4,15- 
19], DX9065a stretches along the active site cleft in an extended 
manner. This conformation is stabilised by the expected salt 
bridge formation of the napthamidine group to Asp-189, by 
hydrophobic interactions between the benzyl spacer and the 
side of the pyrrolidinyl group with the enzyme surface and by 
a weak electrostatic interaction of the basic pyrrolidinyl/acetim- 
idoyl group with a previously unidentified electronegative cav- 
ity of factor Xa. Indirectly, the structural studies in trypsin 
presented here show that this distal basic group searches for 
and is able to recruit hydrogen bonding partners. 
We propose that the additivity of these three interactions 
form the basis for the observed tight binding of DX9065a to 
factor Xa. Anchoring the pyrrolidinyl/acetimidoyl group as 
described could have the added benefit of directing and thereby 
strengthening the hydrophobic interaction. This binding mode 
could also be adopted by the other potent factor Xa inhibitors 
shown in Fig. 1, DABE [8] and BABCH [9]. 
A striking feature of DX9065a is its selectivity for factor Xa 
over thrombin. Katakura et al. [10] have shown that this is 
predominantly a function of the propionic group, leading them 
to propose that this would cause electrostatic repulsion with the 
acidic side chain of thrombin Glu-192. In our model, these 
groups are sufficiently separated that this is not a major effect; 
in any case, thrombin Glu-192 exhibits enhanced flexibility [27]. 
We suggest hat the propionic group would clash with the 
thrombin specific '60-insertion loop', whilst the distal basic 
group cannot be comfortably accommodated due to the inser- 
tion of thrombin residue Glu-97A. An ethyl ester derivative of 
DX9065a is able to inhibit thrombin [10]. We propose that this 
derivative adopts an alternative binding mode, inserting the 
ethyl side chain into the hydrophobic aryl-binding site of 
thrombin, with a concommitant reorientation of the benzyl 
spacer and distal basic group. Thrombin is then inhibited by 
a combination of strong interactions in the S 1 and aryl-binding 
sites with weaker (undetermined) interactions elsewhere. 
Notwithstanding the inadequacies of examining factor Xa 
inhibitors in the context of trypsin, these structural studies 
provide an expedient and plausible model for understanding 
the specificity determinants of factor Xa. It should be noted, 
however, that crystal structures present a static, enthalpic pic- 
ture: other factors uch as changes in entropy and / or solvation 
might play an important role in achieving a low Ki. 
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